It is probably best to avoid naproxen if you have liver cirrhosis.
This is the cautionary advise given:
Nsaids (Includes Naproxen) ↔ Hepatotoxicity
Moderate Potential Hazard, Moderate plausibility
Applies to: Liver Disease
Borderline elevations of serum transaminases, LDH, and alkaline phosphatase have been reported in up to 15% of patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs). These abnormalities may progress, remain unchanged, or regress with continuing therapy. Notable liver enzyme elevations exceeding 3 times the upper limit of normal have been reported in approximately 1% of patients in clinical trials. In addition, rare cases of severe hepatotoxicity, including liver necrosis, hepatic failure, jaundice and fatal fulminant hepatitis, have been reported. Therapy with NSAIDs should be administered cautiously in patients with preexisting liver disease. Periodic monitoring of liver function is recommended during prolonged therapy. NSAIDs are also highly protein-bound and some are extensively metabolized by the liver. Metabolic activity and/or plasma protein binding may be altered in patients with hepatic impairment. A dosage reduction may be required in some cases.
- Naproxen Information for Consumers
- Naproxen Information for Healthcare Professionals (includes dosage details)
- Side Effects of Naproxen (detailed)
Search for questions
Still looking for answers? Try searching for what you seek or ask your own question.